Your browser doesn't support javascript.
loading
Favipiravir in SARS-CoV-2 Infection: Is it Worth it?
Batiha, Gaber El-Saber; Moubarak, Mohamed; Shaheen, Hazem M; Zakariya, Ali M; Usman, Ibe M; Rauf, Abdur; Adhikari, Achyut; Dey, Abhijit; Alexiou, Athanasios; Hetta, Helal F; Al-Gareeb, Ali I; Al-Kuraishy, Hayder M.
Afiliación
  • Batiha GE; Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour 22511, AlBeheira, Egypt.
  • Moubarak M; Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour 22511, AlBeheira, Egypt.
  • Shaheen HM; Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour 22511, AlBeheira, Egypt.
  • Zakariya AM; Department of Biological Sciences, Sule Lamido University Kafin, Hausa, Nigeria.
  • Usman IM; Faculty of Biomedical Sciences, Kampala International University Western Campus, Bushenyi, Uganda.
  • Rauf A; Department of Chemistry, University of Swabi, Swabi, Anbar, KP, Pakistan.
  • Adhikari A; Central Department of Chemistry, Tribhuvan University, Kritipur, Nepal.
  • Dey A; Department. of Life Sciences, Presidency University, Kolkata, India.
  • Alexiou A; Department of Science and Engineering, Novel Global Community Educational Foundation, Australia and AFNP Med, Austria.
  • Hetta HF; Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.
  • Al-Gareeb AI; Department of Clinical Pharmacology, Medicine and Therapeutic, Medical Faculty, College of Medicine, Al-Mustansiriyah University, P.O. Box 14132, Baghdad, Iraq.
  • Al-Kuraishy HM; Department of Clinical Pharmacology, Medicine and Therapeutic, Medical Faculty, College of Medicine, Al-Mustansiriyah University, P.O. Box 14132, Baghdad, Iraq.
Comb Chem High Throughput Screen ; 25(14): 2413-2428, 2022.
Article en En | MEDLINE | ID: mdl-35430987
ABSTRACT
Favipiravir is a potential antiviral drug undergoing clinical trials to manage various viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Favipiravir possesses antiviral properties against RNA viruses, including SARS-CoV-2. Unfortunately, these viruses do not have authorized antiviral drugs for the management of diseases resulting from their infection, hence the dire need to accentuate the discovery of antiviral drugs that are efficacious and have a broad spectrum. Favipiravir acts primarily by blocking inward and outward movements of the virus from cells. Favipiravir is a prodrug undergoing intracellular phosphorylation and ribosylation to form an active form, favipiravir-RTP, which binds viral RNA-dependent RNA polymerase (RdRp). Considering the novel mechanism of favipiravir action, especially in managing viral infections, it is vital to pay more attention to the promised favipiravir hold in the management of SARS-CoV-2, its efficacy, and dosage regimen, and interactions with other drugs. In conclusion, favipiravir possesses antiviral properties against RNA viruses, including COVID- 19. Favipiravir is effective against SARS-CoV-2 infection through inhibition of RdRp. Pre-clinical and large-scalp prospective studies are recommended for efficacy and long-term safety of favipiravir in COVID-19.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virus / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Comb Chem High Throughput Screen Asunto de la revista: BIOLOGIA MOLECULAR / QUIMICA Año: 2022 Tipo del documento: Article País de afiliación: Egipto

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virus / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Comb Chem High Throughput Screen Asunto de la revista: BIOLOGIA MOLECULAR / QUIMICA Año: 2022 Tipo del documento: Article País de afiliación: Egipto